Twenty-four weeks of low-dose semaglutide produced significant reductions in metabolic dysfunction-associated steatotic liver disease (MASLD) severity across all disease stages in 36 HIV-positive adults who achieved clinical weight response (>2.27 kg loss). Using the OWLiver® serum metabolomics panel — a non-invasive alternative to liver biopsy — the SLIM LIVER trial (ACTG A5371) demonstrated measurable histologic-proxy improvements in liver health, validating metabolomics as a viable monitoring tool during GLP-1 receptor agonist therapy.
This finding lands at a critical intersection: people with HIV carry disproportionately high MASLD burden due to antiretroviral-driven metabolic disruption, chronic inflammation, and visceral adiposity — yet they are systematically underrepresented in GLP-1RA trials. Confirming semaglutide's hepatic benefit in this population extends findings from general-population NASH trials (notably ESSENCE and earlier LEAN trial data) into a clinically vulnerable group. The validation of OWLiver® metabolomics as a monitoring surrogate matters practically — liver biopsy remains the gold standard for staging but carries procedural risk and poor patient acceptance, limiting longitudinal tracking.
Critical limitations temper enthusiasm: this is a single-arm, open-label phase 2b trial with no placebo control, a modest responder-only cohort of 36, and metabolomic rather than histologic endpoints. Causality between semaglutide and liver improvement — versus weight loss alone — cannot be fully disentangled. Still, for HIV clinicians managing co-morbid liver disease, this is actionable confirmatory evidence supporting semaglutide use and non-invasive monitoring protocols.
